Categories
Biotech Stocks Featured Stocks to Watch

2 Pharmaceutical Stocks To Watch In 2020; 1 Up 73.08% YTD

Do You Have These 2 Pharmaceutical Stocks On Your 2020 Watchlist?

Pharmaceutical stocks tend to create more momentum when news about developing new medicine or financials about a company are released. Currently, we’re dealing with an economic crisis. However, that does not necessarily affect all top pharmaceutical stocks. Some pharmaceutical stocks will see an increase in trading due to speculation over new developments. But after the news, the hype dies down and the stock either will decline, rise, or maintain its position. The important thing to note is that pharmaceutical stocks are still seeing momentum unlike some other sectors at the moment.

For some pharmaceutical companies who were able to remain open continue developing different types of medicine have held steady financials. On the other hand, some pharmaceutical companies have been very volatile based on developing treatments and vaccines for Covid-19.

That being said, many pharmaceutical stocks related to or not related to the virus are seeing steady momentum. Speculation itself can cause a stock price to go up or down, which can be important for companies. Let’s take a look at two pharmaceutical stocks to watch in 2020.

Read More

Top Pharmaceutical Stocks To Watch In 2020: Actinium

The first pharmaceutical stock to watch is a US-based company Actinium Pharmaceuticals (ATNM Stock Report). Actinium describes itself as a “clinical-stage biopharmaceutical company developing ARC’s or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell-killing ability of radiation.”

ATNM stock is up at 73.08% year-to-date. On June 8th, shares of ATNM stock were trading at $0.32. Investors have increased their hope in this pharmaceutical stock as on June 9th, it rose up to an average of $0.45 a share and a high of $0.53 a share. On June 10th, ATNM stock currently at $0.46 a share, up to $0.12 from just a few days ago. 92 million shares of ATNM stock were traded in the recent session, while its average daily volume was at 6.86 million shares.

Will we see this pharmaceutical stock continue to rise? That will depend on how well it continues to do in its trials and how this pharmaceutical company’s financials look in the future. As stated before pharmaceutical stocks can rise solely on speculation. ATNM stock is near its one year high, so it is fair to say this is a pharmaceutical stock to watch for the future.

Top Pharmaceutical Stocks To Watch In 2020: DelMar

The next pharmaceutical stock to watch on this list is DelMar Pharmaceuticals Inc. (DMPI Stock Report). DelMar describes itself as a pharmaceutical company, “dedicated to the development of novel cancer therapies for patients who are failing or resistant to current treatment regimens.”

Currently, DelMar is studying VAL-083 for patients who have glioblastoma, a type of brain cancer. If the trials for VAL-083 prove to be successful, it can help many people and prove to be very good for DelMar’s financials and DMPI’s stock position. In a statement released by the company:

“VAL-083 is a structurally unique, “first-in-class”, small-molecule DNA-targeting agent. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).”

[Read More] 2 Video Game Stocks To Watch In June

How Have Acquisitions Have Affected DelMar?

On June 10th, DelMar announced that it’s acquiring Adgero Biopharmaceutical to combine its chemotherapeutic platform with Adgero’s photodynamic therapy technology. After this announcement, this DMPI stock saw an increase in its share price. DMPI stock was trading at $1.20 a share before the news broke. On June 10th it saw a spike to a high of $1.43 and it currently sits at $1.34.

As more developments are made with the acquisition, some investors think DMPI’s stock price will continue to rise. Both of these pharmaceutical stocks mentioned above are seeing positive momentum in the market. It is currently unknown where these pharmaceutical stocks will go at the moment. Investors have been looking at these two pharmaceutical companies with a positive outlook for the future.

By Joe Samuel

Joe Samuel is a dedicated stock market researcher and financial contributor. His love for the stock market started at a young age learning from his grandfather. Joe earned a bachelor of science degree in corporate finance and business management. After finishing college, he went the route of an entrepreneur starting numerous businesses and eventually became a financial contributor to a number of outlets including Seeking Alpha, Invesitng.com, and actively contributes to FactSet. At StockMarket.com, Joe looks for emerging stories. One of his traits is identifying new trends before they become mainstream. Whether it’s a biopharmaceutical company debuting a novel treatment or the next technology start-up developing a new platform, Joe looks to be on the cutting edge of that trend.

After years of living in New York, he made the move to Miami, Florida where he’s become an active member of the finance community. Joe has worked with early-stage companies in marketing and consulting capacities, which has given him an opportunity to see what makes companies tick. His viewpoint is that while corporate news is vital to any investment, it’s what isn’t “right in front of you” that can make a good investment great. His approach to the markets is one that aims to deliver information that might not be well-known. But through deep research and diligence, Joe has written about and been able to uncover time-sensitive information when seconds matter in the stock market today.

Joe enjoys covering several stock market sectors. These include commodities, finance, biotechnology, and technology; specifically AI & machine learning. His no-nonsense approach to the market gives readers a cut and dry view of the news that matters most and topics beginning to emerge as new trends in the stock market. He was early to the table with calls on things like the last gold rush in 2019 and has been able to identify influential events and how they could impact certain industries.

During his free time, he enjoys spending time with his family and polishing up one new stock market trends. He’s also an avid car enthusiast with a passion for classic and muscle cars.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments